

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Administration for Children and Families**

[OMB No. 0970-0223]

**Submission for OMB Review; State Self-Assessment Review and Report**

**AGENCY:** Office of Child Support Enforcement, Administration for Children and Families, HHS.

**ACTION:** Request for public comment.

**SUMMARY:** The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF) requests a three-year extension of the State Self-Assessment Review and Report with minor revisions. The information

collected in the reports assists state child support enforcement agencies and OCSE in determining whether the agencies meet federal child support performance requirements. The current Office of Management and Budget (OMB) approval expires April 30, 2022.

**DATES:** *Comments due within 30 days of publication.* OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

**ADDRESSES:** Comments should be sent to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under

30-day Review—Open for Public Comments” or by using the search function.

**SUPPLEMENTARY INFORMATION:**

*Description:* State child support agencies are statutorily required to annually assess the performance of their child support enforcement programs and to provide a report of the findings to the Secretary of HHS. The information collected in the State Self-Assessment Review and Report is a management tool used to determine if states are in compliance with federal child support mandates, to help states evaluate their programs, and to assess their performances.

*Respondents:* States and territories.

**ANNUAL BURDEN ESTIMATES**

Instrument	Total number of annual respondents	Total number of annual responses per respondent	Average annual burden hours per response	Annual burden hours
State Self-Assessment Review and Report (SAR) (SAR Reporting Format and Instructions) .....	54	1	8	432

*Authority:* 42 U.S.C. 654(15)(A); 45 CFR 308.1(e).

Mary B. Jones,  
ACF/OPRE Certifying Officer.

[FR Doc. 2022-04315 Filed 3-1-22; 8:45 am]

BILLING CODE 4184-41-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Administration for Children and Families**

[OMB No. 0970-0320]

**Submission for OMB Review; Tribal Child Support Enforcement Annual Data Report**

**AGENCY:** Office of Child Support Enforcement, Administration for Children and Families, HHS.

**ACTION:** Request for public comment.

**SUMMARY:** The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is requesting a 3-year

extension of the form OCSE-75—Tribal Child Support Enforcement Annual Data Report (OMB #0970-0320, expiration 01/31/2023). There are changes requested to the form.

**DATES:** *Comments due within 30 days of publication.* OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function. You can also obtain copies of the proposed collection of information by emailing [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). Identify all emailed requests by the title of the information collection.

**SUPPLEMENTARY INFORMATION:**

*Description:* The data collected by form OCSE-75 are used to prepare the OCSE preliminary and annual data reports. In addition, tribes administering child support enforcement programs under Title IV-D of the Social Security Act are required to report program status and accomplishments in an annual narrative report as part of the OCSE-75 report and submit it annually. Changes made to the report were agreed to based on several workgroup meetings attended by both OCSE and tribal child support directors. These changes include clarifying data points and definitions.

*Respondents:* Tribal Child Support Enforcement Organizations or the Department/Agency/Bureau responsible for child support enforcement in each tribe.

*Annual Burden Estimates:* Due to the timing required to make system updates to incorporate proposed changes, the current form will be used for fiscal year (FY) 2022 reporting, and the revised form will be implemented beginning FY 2023 reporting.

Instrument	Total number of respondents	Total number of responses per respondent (over 3 years)	Average burden hours per response	Total burden hours	Annual burden hours
OCSE-75 for FY 2022 .....	60	1	40	2,400	2,400

Instrument	Total number of respondents	Total number of responses per respondent (over 3 years)	Average burden hours per response	Total burden hours	Annual burden hours
OCSE-75 for FY 2023 and forward .....	61	2	40	4,880	2,440

*Average Annual Burden Hours: 2,427.*

*Authority:* Title IV–D of the Social Security Act as required by 45 CFR 309.170(b).

**Mary B. Jones,**

*ACF/OPRE Certifying Officer.*

[FR Doc. 2022–04372 Filed 3–1–22; 8:45 am]

**BILLING CODE 4184–41–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2020–D–1317]

#### Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Physician Notification Orders; Guidance for Industry and Food and Drug Administration Staff; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled “Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Physician Notification Orders.” This guidance document describes the processes available to mammography facilities to request additional review of an adverse appeals decision on a facility’s accreditation, and/or a suspension or revocation of certificate, and/or a patient and physician notification order. This guidance supersedes section 4.5 of the Center for Devices and Radiological Health (CDRH) Appeals Processes guidance document dated July 2, 2019.

**DATES:** The announcement of the guidance is published in the **Federal Register** on March 2, 2022.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidance at any time as follows:

#### *Electronic Submissions*

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

#### *Written/Paper Submissions*

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

**Instructions:** All submissions received must include the Docket No. FDA–2020–D–1317 for “Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Physician Notification Orders.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

**Docket:** For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

An electronic copy of the guidance document is available for download from the internet. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the guidance. Submit written requests for a single hard copy of the guidance document entitled “Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation